Excellent results!!!Not only $3.3 mil. is impressive( steady growth quarter be quarter), but also the fact of a new FDA approval of expanded time for Aggrastat( that alone should help to gain new customers and increase revenue) and the upcoming presentation( may attract serious investors ). Looking at those new developments the share price should experience a nice spike. Valuation is much higher than what we see on the market.